MCID: ALL014
MIFTS: 38

Allergic Encephalomyelitis

Categories: Immune diseases, Rare diseases

Aliases & Classifications for Allergic Encephalomyelitis

MalaCards integrated aliases for Allergic Encephalomyelitis:

Name: Allergic Encephalomyelitis 52
Experimental Autoimmune Encephalomyelitis 71

Classifications:



External Ids:

UMLS 71 C0014072

Summaries for Allergic Encephalomyelitis

MalaCards based summary : Allergic Encephalomyelitis, also known as experimental autoimmune encephalomyelitis, is related to myelitis and optic neuritis. An important gene associated with Allergic Encephalomyelitis is MBP (Myelin Basic Protein), and among its related pathways/superpathways are CCR5 Pathway in Macrophages and Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions. The drugs Dopamine and Risperidone have been mentioned in the context of this disorder. Affiliated tissues include t cells, brain and spinal cord, and related phenotype is Reduced mammosphere formation.

Related Diseases for Allergic Encephalomyelitis

Diseases related to Allergic Encephalomyelitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 180)
# Related Disease Score Top Affiliating Genes
1 myelitis 30.4 MOG MBP
2 optic neuritis 30.2 PLP1 MOG MBP
3 acute disseminated encephalomyelitis 30.2 MOG MBP
4 autoimmune disease 30.0 PLP1 MOG MBP CCL5 CCL2
5 guillain-barre syndrome 29.9 MOG MBP
6 spinal cord disease 29.9 MOG MBP
7 neuromyelitis optica 29.9 MOG MBP
8 proteasome-associated autoinflammatory syndrome 1 29.4 CCL5 CCL3 CCL2
9 tuberculous meningitis 29.4 CCL3 CCL2
10 central nervous system disease 29.4 PLP1 MOG MBP CCL2
11 tropical spastic paraparesis 29.4 CCL5 CCL3
12 encephalitis 29.0 MOG CCL5 CCL3 CCL2
13 demyelinating disease 28.9 PLP1 MOG MBP CCL5 CCL3 CCL2
14 neuritis 28.9 MOG MBP CCL5 CCL3 CCL2
15 autoimmune disease of central nervous system 28.8 MOG MBP CCL5 CCL2
16 multiple sclerosis 28.5 PLP1 MOG MBP CCL5 CCL3 CCL2
17 relapsing-remitting multiple sclerosis 27.6 PLP1 MOG MBP CCL5 CCL3 CCL2
18 pertussis 10.7
19 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.6
20 allergic hypersensitivity disease 10.6
21 cytokine deficiency 10.4
22 encephalopathy 10.4
23 paraplegia 10.4
24 ataxia and polyneuropathy, adult-onset 10.3
25 vaccinia 10.3
26 nervous system disease 10.3
27 orchitis 10.3
28 vasculitis 10.3
29 uveitis 10.2
30 lymphopenia 10.2
31 measles 10.2
32 hereditary neuropathies 10.2 PLP1 MBP
33 leukodystrophy, hypomyelinating, 2 10.2 PLP1 MBP
34 niemann-pick disease, type a 10.2 PLP1 MBP
35 niemann-pick disease 10.2 PLP1 MBP
36 canavan disease 10.1 PLP1 MBP
37 balo concentric sclerosis 10.1 MOG MBP
38 autoimmune optic neuritis 10.1 MOG MBP
39 internuclear ophthalmoplegia 10.1 MOG MBP
40 krabbe disease 10.1 PLP1 MBP
41 rabies 10.1
42 gout 10.1
43 thyroiditis 10.1
44 iridocyclitis 10.1
45 48,xyyy 10.1
46 tremor 10.1
47 autoimmune disease of peripheral nervous system 10.1 MOG MBP
48 chronic inflammatory demyelinating polyradiculoneuropathy 10.1 MBP CCL5
49 polyradiculoneuropathy 10.1 MBP CCL5
50 subacute sclerosing panencephalitis 10.1 MOG MBP

Graphical network of the top 20 diseases related to Allergic Encephalomyelitis:



Diseases related to Allergic Encephalomyelitis

Symptoms & Phenotypes for Allergic Encephalomyelitis

GenomeRNAi Phenotypes related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 8.92 CCL2 CCL3 MOG PLP1

Drugs & Therapeutics for Allergic Encephalomyelitis

Drugs for Allergic Encephalomyelitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 88)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 2 51-61-6, 62-31-7 681
2
Risperidone Approved, Investigational Phase 2 106266-06-2 5073
3
Selenium Approved, Investigational, Vet_approved Phase 1, Phase 2 7782-49-2
4
Tocopherol Approved, Investigational Phase 1, Phase 2 1406-66-2, 54-28-4 14986
5
Lamotrigine Approved, Investigational Phase 2 84057-84-1 3878
6
Testosterone Approved, Experimental, Investigational Phase 1, Phase 2 58-22-0, 481-30-1 10204 6013
7
Testosterone enanthate Approved Phase 1, Phase 2 315-37-7 9416
8
Testosterone undecanoate Approved, Investigational Phase 1, Phase 2 5949-44-0
9
Methyltestosterone Approved Phase 1, Phase 2 58-18-4 6010
10
Interferon beta-1b Approved Phase 2 145155-23-3
11
Atorvastatin Approved Phase 2 134523-00-5 60823
12
Prednisolone phosphate Approved, Vet_approved Phase 1, Phase 2 302-25-0
13
Methylprednisolone Approved, Vet_approved Phase 1, Phase 2 83-43-2 6741
14
Methylprednisolone hemisuccinate Approved Phase 1, Phase 2 2921-57-5
15
Prednisone Approved, Vet_approved Phase 1, Phase 2 53-03-2 5865
16
Prednisolone Approved, Vet_approved Phase 1, Phase 2 50-24-8 5755
17 Prednisolone acetate Approved, Vet_approved Phase 1, Phase 2 52-21-1
18
Simvastatin Approved Phase 2 79902-63-9 54454
19
Minocycline Approved, Investigational Phase 2 10118-90-8 5281021
20
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
21
Vitamin E Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-02-9 14985
22
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
23 Tocotrienol Investigational Phase 1, Phase 2 6829-55-6
24
Prednisolone hemisuccinate Experimental Phase 1, Phase 2 2920-86-7
25 Dopamine Agents Phase 2
26 Dopamine Antagonists Phase 2
27 Trace Elements Phase 1, Phase 2
28 Micronutrients Phase 1, Phase 2
29 Vitamins Phase 1, Phase 2
30 Nutrients Phase 1, Phase 2
31 Calcium, Dietary Phase 2
32 Alpha-lipoic Acid Phase 1, Phase 2
33 Vitamin B Complex Phase 1, Phase 2
34 Antioxidants Phase 1, Phase 2
35 Thioctic Acid Phase 1, Phase 2
36 Folate Phase 1, Phase 2
37 Ginkgo Phase 1, Phase 2
38 Tocotrienols Phase 1, Phase 2
39 Tocopherols Phase 1, Phase 2
40 Vitamin B9 Phase 1, Phase 2
41 Sodium Channel Blockers Phase 2
42 Psychotropic Drugs Phase 2
43 Anticonvulsants Phase 2
44 Antipsychotic Agents Phase 2
45 Diuretics, Potassium Sparing Phase 2
46 calcium channel blockers Phase 2
47 Testosterone 17 beta-cypionate Phase 1, Phase 2
48 Androgens Phase 1, Phase 2
49 Anabolic Agents Phase 1, Phase 2
50 Antiviral Agents Phase 2

Interventional clinical trials:

(show all 28)
# Name Status NCT ID Phase Drugs
1 Effects of Short-chain Fatty Acids, Here Sodium Propionate, a Metabolism Product of the Human Gut-microbiome, on Inflammatory and Metabolic Parameters in Patients on Maintenance Hemodialysis - a Pilot Study Unknown status NCT02976688 Phase 2, Phase 3
2 The Effect of MS14 in Association With Risperidone in Treatment of Schizophrenia: A Double Blind Randomized Control Trial Unknown status NCT01083381 Phase 2 MS14;Risperidone
3 Natural Antioxidants in the Treatment of Multiple Sclerosis Completed NCT00010842 Phase 1, Phase 2 Ginkgo biloba;Alpha-lipoic acid;Vitamin E/Selenium;Essential fatty acids
4 Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis Completed NCT01377870 Phase 1, Phase 2
5 A Randomised Controlled Trial of Neuroprotection With Lamotrigine in Secondary Progressive Multiple Sclerosis: Single Centre, Phase 2 Trial Completed NCT00257855 Phase 2 Lamotrigine
6 Testosterone Treatment for Multiple Sclerosis: A Preliminary Trial Completed NCT00405353 Phase 1, Phase 2 Androgel 10 grams of gel containing 100 mg of testosterone
7 Short-Term Effects of Medicinal Cannabis Therapy on Spasticity in Multiple Sclerosis Completed NCT00248378 Phase 1, Phase 2 Smoked Cannabis
8 Explorative Trial to Investigate the Migration Ability of Mesenchymal Bone Marrow Stem Cells (MSC) in the Central Nervous System (CNS) Following Their Intrathecal Administration in Severe Cases of Multiple Sclerosis (MS) Completed NCT00781872 Phase 1, Phase 2
9 SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study ("SWABIMS Follow Up-study") Completed NCT01111656 Phase 2 Interferon beta-1b group;Interferon beta-1b/Atorvastatin group
10 Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis. Completed NCT00942591 Phase 2 Interferon beta 1b;Atorvastatin
11 Double-blind, Placebo-controlled, Randomized Study of the Safety and Tolerability of Isoxsuprine HCL Combined With High Dose Steroid Treatment of Multiple Sclerosis (MS) Relapse Recruiting NCT03752307 Phase 1, Phase 2 Isoxsuprine Hydrochloride;Placebo;Corticosteroid
12 A Double-blind, Randomised, Placebo-controlled Single-site Study of High Dose Simvastatin Treatment for Secondary Progressive Multiple Sclerosis: Impact on Vascular Perfusion and Oxidative Damage Recruiting NCT03896217 Phase 2 Simvastatin
13 A Multi-centre, Double Blind, Randomized, Placebo Controlled, Parallel Group Trial Investigating Minocycline Versus Placebo as Add-on Therapy in Patients Who Are on Treatment With Interferon-beta-1a 44 Mcg Tiw (Rebif®) for the Treatment of Relapsing-Remitting Multiple Sclerosis Terminated NCT01134627 Phase 2 Minocycline;Placebo
14 Phase II Study of High Dose Cyclophosphamide Followed by Glatiramer Acetate in the Treatment of Relapsing Remitting Multiple Sclerosis Withdrawn NCT00939549 Phase 2 Cyclophosphamide/Glatiramer acetate
15 An Open-label, Randomised, Crossover Study to Assess the Relative Bioavailability of Different 2mg Formulations of GSK2018682(S1P1 Agonist) in Healthy Volunteers Completed NCT01466322 Phase 1 GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state
16 to Investigate the Maternal Serum IL-17 Levels in Pregnant Women With Intrahepatic Cholestasis of Pregnancy Unknown status NCT01898832
17 The Effect of a Gluten Free Diet on the Permeability of the Blood Brain Barrier in Patients With Clinically Isolated Syndrome Measured by Dynamic Contrast Enhanced Magnetic Resonance Imaging Unknown status NCT03451955
18 Comparison Between Clinical and MRI Multiple Sclerosis Activity and Expression of Human Endogenous Retrovirus Type W and Herpesvirus in Peripheral Blood of Patients Unknown status NCT02489877
19 A Pilot Study of Intermittent Calorie Restriction in Multiple Sclerosis Completed NCT02647502
20 Isfahan University of Medical Sciences Completed NCT02696590
21 Evaluation of the Influence of Salt Intake on TH17 Interleukin(IL)-17 Producing CD4+ Helper T Cells in Human Subjects Completed NCT02261688
22 The Role of Sodium Chloride and the Treg/Th17 Axis in Autoimmune Hepatitis Recruiting NCT02050646
23 The Role of IL-II in the Development of Autoimmune Response in Multiple Sclerosis Recruiting NCT03735823
24 The Effect of the Ketogenic Diet on Patients With Relapsing Remitting Multiple Sclerosis Recruiting NCT03718247
25 Immunoassay and Regulation of Traditional Chinese Medicine on Cancer Patients Recruiting NCT04438564
26 Involvement of Immune Cells Derived From the Intestine in Sjogren's Syndrome Not yet recruiting NCT03841318
27 Calorie Restriction as a Novel Therapeutic Tool to Manipulate Immunity and Improve Therapeutic Potential of First Line Drug Treatments During Relapsing Remitting Multiple Sclerosis Not yet recruiting NCT04042415
28 Clinical Relevance of miR-142-3p as Potential Biomarker of Synaptopathy in Multiple Sclerosis Not yet recruiting NCT03999788

Search NIH Clinical Center for Allergic Encephalomyelitis

Genetic Tests for Allergic Encephalomyelitis

Anatomical Context for Allergic Encephalomyelitis

MalaCards organs/tissues related to Allergic Encephalomyelitis:

40
T Cells, Brain, Spinal Cord, B Cells, Bone, Endothelial, Monocytes

Publications for Allergic Encephalomyelitis

Articles related to Allergic Encephalomyelitis:

(show top 50) (show all 11358)
# Title Authors PMID Year
1
Should mast cells be considered therapeutic targets in multiple sclerosis? 61
32394947 2020
2
MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis. 61
32246624 2020
3
Neuronal interleukin-1 receptors mediate pain in chronic inflammatory diseases. 61
32573694 2020
4
NK cell receptor NKG2D enforces proinflammatory features and pathogenicity of Th1 and Th17 cells. 61
32453422 2020
5
Performance of compressed sensing for fluorine-19 magnetic resonance imaging at low signal-to-noise ratio conditions. 61
31863516 2020
6
Transplantation of IFN-γ Primed hUCMSCs Significantly Improved Outcomes of Experimental Autoimmune Encephalomyelitis in a Mouse Model. 61
32172400 2020
7
Evaluation of cell transplant-mediated attenuation of diffuse injury in experimental autoimmune encephalomyelitis using onVDMP CEST MRI. 61
32304749 2020
8
Down-regulated miR-374c and Hsp70 promote Th17 cell differentiation by inducing Fas expression in experimental autoimmune encephalomyelitis. 61
31756487 2020
9
The endothelial basement membrane acts as a checkpoint for entry of pathogenic T cells into the brain. 61
32379272 2020
10
Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis. 61
32229332 2020
11
Complement-dependent synapse loss and microgliosis in a mouse model of multiple sclerosis. 61
32151684 2020
12
Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis. 61
32293054 2020
13
Regulatory T cells promote remyelination in the murine experimental autoimmune encephalomyelitis model of multiple sclerosis following human neural stem cell transplant. 61
32276110 2020
14
Novel phloroglucinol derivative Compound 21 protects experimental autoimmune encephalomyelitis rats via inhibiting Th1/Th17 cell infiltration. 61
32173452 2020
15
Natural product piperine alleviates experimental allergic encephalomyelitis in mice by targeting dihydroorotate dehydrogenase. 61
32353424 2020
16
Alendronate alleviates the symptoms of experimental autoimmune encephalomyelitis. 61
32361191 2020
17
Expression of hypothalamic feeding-related peptide genes and neuroendocrine responses in an experimental allergic encephalomyelitis rat model. 61
32298774 2020
18
Antibodies to the RNA binding protein heterogeneous nuclear ribonucleoprotein A1 contribute to neuronal cell loss in an animal model of multiple sclerosis. 61
31872424 2020
19
A silent agonist of α7 nicotinic acetylcholine receptors modulates inflammation ex vivo and attenuates EAE. 61
31874200 2020
20
Oligodendrocyte ARNT2 expression is altered in models of MS. 61
32439712 2020
21
Oral chitin treatment improved demyelination in murine autoimmune encephalomyelitis model by inhibition of inflammatory responses. 61
32361654 2020
22
Dimethyl fumarate suppresses granulocyte macrophage colony-stimulating factor-producing Th1 cells in CNS neuroinflammation. 61
32371548 2020
23
Protective effects of pharmacological therapies in animal models of multiple sclerosis: a review of studies 2014-2019. 61
31960801 2020
24
The proportion of myeloid-derived suppressor cells in the spleen is related to the severity of the clinical course and tissue damage extent in a murine model of multiple sclerosis. 61
32278882 2020
25
Rapamycin and MCC950 modified gut microbiota in experimental autoimmune encephalomyelitis mouse by brain gut axis. 61
32376270 2020
26
Intranasal administration of conditioned medium derived from mesenchymal stem cells-differentiated oligodendrocytes ameliorates experimental autoimmune encephalomyelitis. 61
32353514 2020
27
Upregulation of Cathepsins in Olfactory Bulbs Is Associated with Transient Olfactory Dysfunction in Mice with Experimental Autoimmune Encephalomyelitis. 61
32529488 2020
28
A GM-CSF-neuroantigen tolerogenic vaccine elicits inefficient antigen recognition events below the CD40L triggering threshold to expand CD4+ CD25+ FOXP3+ Tregs that inhibit experimental autoimmune encephalomyelitis (EAE). 61
32522287 2020
29
Tetrameric PKM2 Activation Curbs CD4+ T Cell Overactivation. 61
32340764 2020
30
Glatiramer acetate increases T- and B -regulatory cells and decreases granulocyte-macrophage colony-stimulating factor (GM-CSF) in an animal model of multiple sclerosis. 61
32534388 2020
31
Functional role of endogenous Kv1.4 in experimental demyelination. 61
32247877 2020
32
Comprehensive Analysis of the Immune and Stromal Compartments of the CNS in EAE Mice Reveal Pathways by Which Chloroquine Suppresses Neuroinflammation. 61
32516999 2020
33
Orexin/hypocretinin in multiple sclerosis and experimental autoimmune encephalomyelitis. 61
31823881 2020
34
Gut commensals, dysbiosis, and immune response imbalance in the pathogenesis of multiple sclerosis. 61
32507072 2020
35
Possible Correlation between Cholinergic System Alterations and Neuro/Inflammation in Multiple Sclerosis. 61
32521719 2020
36
The MicroRNA miR-22 Represses Th17 Cell Pathogenicity by Targeting PTEN-Regulated Pathways. 61
32518131 2020
37
Epstein Barr virus-immortalized B lymphocytes exacerbate experimental autoimmune encephalomyelitis in xenograft mice. 61
32543727 2020
38
Changes of immune parameters of T lymphocytes and macrophages in EAE mice after BM-MSCs transplanation. 61
32544469 2020
39
T Cell Delivery of Nanoparticles-Bound Anti-CD20 Monoclonal Antibody: Successful B Cell Depletion in the Spinal Cord during Experimental Autoimmune Encephalomyelitis. 61
32514635 2020
40
Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System. 61
32498357 2020
41
Targeting Dendritic Cells with Antigen-Delivering Antibodies for Amelioration of Autoimmunity in Animal Models of Multiple Sclerosis and Other Autoimmune Diseases. 61
32549343 2020
42
P2Y6 Deficiency Enhances Dendritic Cell-Mediated Th1/Th17 Differentiation and Aggravates Experimental Autoimmune Encephalomyelitis. 61
32554432 2020
43
Transcriptomics and proteomics reveal a cooperation between interferon and T-helper 17 cells in neuromyelitis optica. 61
32503977 2020
44
The impact of regional astrocyte interferon-γ signaling during chronic autoimmunity: a novel role for the immunoproteasome. 61
32532298 2020
45
Regulatory B cells in infection, inflammation, and autoimmunity. 61
32143836 2020
46
Immune Autoregulatory CD8 T Cells Require IFN-γ Responsiveness to Optimally Suppress Central Nervous System Autoimmunity. 61
32532836 2020
47
Salt generates anti-inflammatory Th17 cells but amplifies their pathogenicity in pro-inflammatory cytokine microenvironments. 61
32484796 2020
48
Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid-β had distinct effects on neuropathology and cognitive deficits in EAE/AD mice. 61
32034757 2020
49
CNS-localized myeloid cells capture living invading T cells during neuroinflammation. 61
32219436 2020
50
Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-α-dependent pathways. 61
32409602 2020

Variations for Allergic Encephalomyelitis

Expression for Allergic Encephalomyelitis

Search GEO for disease gene expression data for Allergic Encephalomyelitis.

Pathways for Allergic Encephalomyelitis

Pathways related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 CCL5 CCL3 CCL2
2
Show member pathways
11.88 CCL5 CCL3 CCL2
3 11.3 CCL5 CCL3 CCL2
4 10.93 CCL5 CCL3 CCL2
5 10.53 CCL3 CCL2
6 10.49 CCL5 CCL3 CCL2
7 10.48 CCL5 CCL3 CCL2
8 10.16 PLP1 MBP

GO Terms for Allergic Encephalomyelitis

Cellular components related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 myelin sheath GO:0043209 8.62 PLP1 MBP

Biological processes related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.88 MBP CCL5 CCL3 CCL2
2 inflammatory response GO:0006954 9.85 PLP1 CCL5 CCL3 CCL2
3 positive regulation of GTPase activity GO:0043547 9.82 CCL5 CCL3 CCL2
4 cytokine-mediated signaling pathway GO:0019221 9.81 CCL5 CCL3 CCL2
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.79 CCL5 CCL3 CCL2
6 chemotaxis GO:0006935 9.78 CCL5 CCL3 CCL2
7 cellular response to tumor necrosis factor GO:0071356 9.77 CCL5 CCL3 CCL2
8 cellular response to interferon-gamma GO:0071346 9.75 CCL5 CCL3 CCL2
9 response to toxic substance GO:0009636 9.74 MBP CCL5 CCL3
10 cell chemotaxis GO:0060326 9.71 CCL5 CCL3 CCL2
11 MAPK cascade GO:0000165 9.71 MBP CCL5 CCL3 CCL2
12 cellular response to interleukin-1 GO:0071347 9.67 CCL5 CCL3 CCL2
13 myelination GO:0042552 9.65 PLP1 MBP
14 positive chemotaxis GO:0050918 9.65 CCL5 CCL3
15 neutrophil chemotaxis GO:0030593 9.65 CCL5 CCL3 CCL2
16 substantia nigra development GO:0021762 9.64 PLP1 MBP
17 cellular response to fibroblast growth factor stimulus GO:0044344 9.63 CCL5 CCL2
18 chemokine-mediated signaling pathway GO:0070098 9.63 CCL5 CCL3 CCL2
19 positive regulation of calcium ion transport GO:0051928 9.62 CCL5 CCL3
20 positive regulation of calcium ion import GO:0090280 9.61 CCL3 CCL2
21 cellular response to organic cyclic compound GO:0071407 9.61 CCL5 CCL3 CCL2
22 negative regulation by host of viral transcription GO:0043922 9.6 CCL5 CCL3
23 axon ensheathment GO:0008366 9.56 PLP1 MBP
24 monocyte chemotaxis GO:0002548 9.54 CCL5 CCL3 CCL2
25 positive regulation of natural killer cell chemotaxis GO:2000503 9.52 CCL5 CCL3
26 astrocyte cell migration GO:0043615 9.51 CCL3 CCL2
27 protein kinase B signaling GO:0043491 9.5 CCL5 CCL3 CCL2
28 lymphocyte chemotaxis GO:0048247 9.43 CCL5 CCL3 CCL2
29 lipopolysaccharide-mediated signaling pathway GO:0031663 9.33 CCL5 CCL3 CCL2
30 eosinophil chemotaxis GO:0048245 9.13 CCL5 CCL3 CCL2
31 macrophage chemotaxis GO:0048246 8.8 CCL5 CCL3 CCL2

Molecular functions related to Allergic Encephalomyelitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.63 CCL5 CCL3 CCL2
2 cytokine activity GO:0005125 9.58 CCL5 CCL3 CCL2
3 chemoattractant activity GO:0042056 9.43 CCL5 CCL3
4 structural constituent of myelin sheath GO:0019911 9.37 PLP1 MBP
5 CCR5 chemokine receptor binding GO:0031730 9.32 CCL5 CCL3
6 phospholipase activator activity GO:0016004 9.26 CCL5 CCL3
7 CCR1 chemokine receptor binding GO:0031726 9.16 CCL5 CCL3
8 chemokine activity GO:0008009 9.13 CCL5 CCL3 CCL2
9 CCR chemokine receptor binding GO:0048020 8.8 CCL5 CCL3 CCL2

Sources for Allergic Encephalomyelitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....